INCY: Q2 revenue up 38% to $1.67B; 2026 guidance raised on strong Opzelura and oncology growth
Revenue grew 38% year-over-year to $1.67B, driven by strong product demand and a one-time CMS benefit. Guidance for 2026 was raised across net sales and key franchises, with Opzelura and hematology/oncology segments showing robust growth.Based on Incyte Corporation [INCY] Q2 2026 Audio Transcript —…